- Home
- AIRT vs RPTX Comparison
AIRT vs RPTX Comparison
Compare AIRT & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- RPTX
- Stock Information
- Founded
- AIRT 1980
- RPTX 2016
- Country
- AIRT United States
- RPTX Canada
- Employees
- AIRT N/A
- RPTX N/A
- Industry
- AIRT Air Freight/Delivery Services
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- RPTX Health Care
- Exchange
- AIRT Nasdaq
- RPTX Nasdaq
- Market Cap
- AIRT 63.8M
- RPTX 72.6M
- IPO Year
- AIRT N/A
- RPTX 2020
- Fundamental
- Price
- AIRT N/A
- RPTX $1.87
- Analyst Decision
- AIRT
- RPTX Strong Buy
- Analyst Count
- AIRT 0
- RPTX 3
- Target Price
- AIRT N/A
- RPTX $4.50
- AVG Volume (30 Days)
- AIRT 1.2K
- RPTX 93.7K
- Earning Date
- AIRT 11-11-2025
- RPTX 11-06-2025
- Dividend Yield
- AIRT N/A
- RPTX N/A
- EPS Growth
- AIRT N/A
- RPTX N/A
- EPS
- AIRT N/A
- RPTX N/A
- Revenue
- AIRT $296,309,000.00
- RPTX $250,000.00
- Revenue This Year
- AIRT N/A
- RPTX N/A
- Revenue Next Year
- AIRT N/A
- RPTX N/A
- P/E Ratio
- AIRT N/A
- RPTX N/A
- Revenue Growth
- AIRT 5.14
- RPTX N/A
- 52 Week Low
- AIRT $14.56
- RPTX $0.89
- 52 Week High
- AIRT $26.70
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- AIRT 49.54
- RPTX 67.88
- Support Level
- AIRT $22.00
- RPTX $1.67
- Resistance Level
- AIRT $23.31
- RPTX $1.88
- Average True Range (ATR)
- AIRT 0.31
- RPTX 0.06
- MACD
- AIRT -0.20
- RPTX 0.01
- Stochastic Oscillator
- AIRT 30.96
- RPTX 99.77
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.